Cabot Brown - GW Pharmaceuticals Non-Executive Independent Director
Director
Mr. Cabot Brown is NonExecutive Independent Director of GW Pharmaceuticals PLC. Mr. Brown has over 25 years of experience in the financial industry. Mr. Brown is the Founder and Chief Executive Officer of Carabiner LLC, an advisory and private equity firm based in San Francisco and London that specializes in health care and education. Previously, Mr. Brown served as a Managing Director at GCA Savvian Group Corporationration, an international financial advisory firm, from 2011 to 2012 where he directed the firm efforts in the health care industry. Before joining GCA Savvian, Mr. Brown worked for ten years at Seven Hills Group, an investment banking group he cofounded where he also directed the firm health care activities. He also was Managing Director of Brown, McMillan Co., an investment firm he cofounded that sponsored buyouts and VC investments. From 1987 until 1995, Mr. Brown worked at Volpe, Welty Company, a boutique investment bank where he cofounded and ran the health care practice and served as a member of its Executive Committee. Mr. Brown started his finance career in New York, working in the investment banking departments of The First Boston Corporation and Lehman Brothers since 2013.
| Age | 52 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | (44) 1223 235667 |
| Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Andre Wilkens | Harmony Gold Mining | 68 | |
| Arnold Steiner | Old Republic International | 83 | |
| Mavuso Msimang | Harmony Gold Mining | 75 | |
| Rate Margareta | Vindicator Silver Lead Mining | 37 | |
| Matthew Scully | Perseus Mining Limited | N/A | |
| Lori Greeley | Brp Group | 57 | |
| Charles Titterton | Old Republic International | 76 | |
| Joaquim Chissano | Harmony Gold Mining | 78 | |
| Simo Lushaba | Harmony Gold Mining | 51 | |
| John Dixon | Old Republic International | 81 | |
| Lee Capps | Brp Group | 69 | |
| Joseph Cantie | Summit Materials | 57 | |
| Colin Carson | Perseus Mining Limited | N/A | |
| Patricia McGinnis | Brp Group | 69 | |
| Mashego Mashego | Harmony Gold Mining | 45 | |
| Patrick McGinnis | Brp Group | 70 | |
| Peter McNitt | Old Republic International | 66 | |
| Charles Kovaleskias | Old Republic International | N/A | |
| Charles Kovaleski | Old Republic International | 72 | |
| Frank Abbott | Harmony Gold Mining | 62 | |
| Lisa Caldwell | Old Republic International | 60 | |
Management Performance
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Waldegrave, Non-Executive Independent Director | ||
| Christopher Tovey, COO, Executive Director | ||
| Thomas Lynch, Non-Executive Independent Director | ||
| Catherine Mackey, Non-Executive Independent Director | ||
| Justin Gover, CEO, Director | ||
| Geoffrey Guy, Executive Chairman of the Board | ||
| James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
| Julian Gangolli, Executive Director | ||
| Alicia Secor, Non-Executive Independent Director | ||
| Adam George, CFO, Company Secretary, Director | ||
| Cabot Brown, Non-Executive Independent Director | ||
| Stephen Wright, Research & Development Director, Executive Director | ||
| Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 | |||
| Profit Margin | (11.03) % | |||
| Operating Margin | (9.82) % | |||
| Current Valuation | 6.42 B | |||
| Shares Outstanding | 31.54 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.35 % | |||
| Number Of Shares Shorted | 693.73 K | |||
| Price To Earning | 126.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |